Use of Interferon-Inducible 2',5'-Oligoadenylate-Dependent RNase in the Diagnosis, Prognosis, and Treatment of Prostate Cancer
Description of Invention:
This invention pertains to the use of interferon-inducible 2',5'-oligoadenlyate-dependent RNase L in the diagnosis, prognosis and treatment of cancer, particularly prostate cancer. The inventors have identified a potential prostate cancer susceptibility locus, which has been designated HPC1 due to its putative link to hereditary prostate cancer. HPC1 may lead to an early, sensitive and accurate method for detecting cancer or a predisposition to cancer, especially prostate cancer, in a mammal. In addition, such claimed methods can be used to monitor onset and progression of cancer, as well as a patient's response to a particular treatment.
Inventors:
J. Carpten (NHGRI) J. Trent (NHGRI) J. Smith P. Walsh W. Isaacs D. Stephan N. Nupponen (NHGRI)
Patent Status:
DHHS Reference No. E-196-2001/0 --
PCT Application PCT/US02/19516 filed 20 Jun 2002, which published as WO 03/000112 on 21 Dec 2002, claiming priority to a U.S. Provisional Patent Application filed on 20 Jun 2001
Portfolios: Cancer
Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
